A 55-year-old woman with acute coronary syndrome is prescribed dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. Which is the most common cause of clopidogrel resistance in clinical practice?

Explanation

## Clopidogrel Resistance: Most Common Cause ### Definition Clopidogrel resistance is defined as inadequate platelet inhibition despite standard dosing. It is associated with increased risk of stent thrombosis and recurrent ischemic events. ### Why CYP2C19 Genetic Polymorphism Is the Most Common Cause **Key Point:** Clopidogrel is a **prodrug** that requires hepatic bioactivation via the CYP2C19 enzyme to generate its active thiol metabolite, which irreversibly inhibits the platelet P2Y12 receptor. - **Loss-of-function (LOF) alleles** — CYP2C19\*2 (most common), \*3, \*4, \*5 — reduce or abolish enzyme activity, leading to decreased active metabolite formation and inadequate platelet inhibition. - Prevalence of at least one LOF allele: ~25–30% in Caucasians; **50–60% in East Asians** (highly relevant for Indian/Asian populations tested in NEET PG). - CYP2C19 polymorphism is the **most consistently documented, pharmacologically defined, and clinically validated** cause of true clopidogrel resistance across major guidelines (ACC/AHA, ESC) and pharmacology textbooks (KD Tripathi 8e, Goodman & Gilman). ### Classification of Causes | Category | Mechanism | Notes | |----------|-----------|-------| | **Genetic (CYP2C19 LOF)** | Reduced prodrug activation | **Most common intrinsic cause; highest clinical evidence** | | **Drug–drug interaction (PPIs)** | Omeprazole/lansoprazole inhibit CYP2C19 | Significant but secondary | | **Non-adherence** | Missed doses | Operational/real-world factor, not true pharmacological resistance | | **Elevated platelet count** | Thrombocytosis overwhelms inhibition | Rare (<2%) | ### Distinguishing "True Resistance" vs. "Apparent Resistance" - **Non-adherence** causes *apparent* resistance (the drug was never taken), not pharmacological resistance. In pharmacology and exam contexts, "clopidogrel resistance" refers to inadequate platelet inhibition **despite adequate drug intake**. - The stem specifies "clopidogrel resistance in clinical practice," which in pharmacological literature refers to the intrinsic failure of the drug to achieve its effect — best explained by CYP2C19 polymorphism. ### Drug–Drug Interaction: PPIs - Omeprazole and lansoprazole are CYP2C19 inhibitors and reduce clopidogrel activation by 25–50%. - **Pantoprazole and rabeprazole** have minimal CYP2C19 interaction and are preferred with clopidogrel. - This is a real but secondary cause compared to genetic polymorphism. ### Alternatives When CYP2C19 LOF Is Identified - **Prasugrel:** Activated via CYP3A4/CYP2B6; NOT affected by CYP2C19 polymorphism — preferred in poor metabolizers. - **Ticagrelor:** Direct-acting (not a prodrug); bypasses CYP2C19 entirely — superior outcomes in ACS (PLATO trial). **Clinical Pearl:** Genetic testing for CYP2C19 is recommended by the FDA (black-box warning on clopidogrel) in high-risk patients. Poor metabolizers (CYP2C19\*2/\*2) should be switched to prasugrel or ticagrelor. **High-Yield:** CYP2C19 genetic polymorphism is the most common and pharmacologically established cause of clopidogrel resistance — a cornerstone concept in NEET PG pharmacology. [cite: KD Tripathi 8e Ch 18; Goodman & Gilman 13e; ACC/AHA DAPT Guidelines 2016]